Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Aug 27, 2012Clinical Study Seeks to Evaluate MORAb-004 Plus the Standard of Care for Extending Progression-Free Survival of Patients with Metastatic Soft Tissue Sarcoma
Morphotek(®), Inc. announced today that it has commenced a multi-center, Phase II study evaluating the safety and efficacy of MORAb-004 when combined...
-
Aug 20, 2012
Eisai Inc. announced today that the results of two studies: "Evaluation of Adjunctive Perampanel in Patients with Refractory Partial Onset...
-
Aug 14, 2012Facility Will Help Accelerate Early-Stage Clinical Trials of Biologics
Morphotek(®), Inc., a wholly-owned subsidiary of Eisai Co., Ltd., today celebrated the grand opening of a new pilot manufacturing plant for the...
-
Aug 8, 2012Together The Eisai Women's Oncology Program, CANCERcare, Cancer Support Community and Meals On Wheels Association of America Are Working to Help Ease the Stress of Those Living with Breast Cancer
Woodcliff Lake, NJ, Augugst 8, 2012 - Magnolia Meals at Home™, a new program bringing free, nutritious meals to patients living with breast cancer and their families, is now being piloted in and...
-
Jul 30, 2012Eisai Plans to Submit Applications for Marketing Approval throughout the Americas
WOODCLIFF LAKE, NJ, and SAN DIEGO, CA, July 30, 2012 -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that Arena has transferred the BELVIQ® (lorcaserin hydrochloride)...
-
Jul 25, 2012
Eisai Inc. announced today that the results of the study, "Adjunctive Perampanel For Refractory Partial-Onset Seizures: Randomized Phase III...
-
Jul 9, 2012
Eisai Inc. today announced preliminary results from a recently completed phase III study of Halaven versus capecitabine (Xeloda®) in women with...
-
Jun 27, 2012-- First Prescription Weight-Loss Treatment Approved by FDA in 13 Years -- Eisai to Launch BELVIQ in U.S. Following DEA's Completion of Scheduling Review --
San Diego, CA, and Woodcliff Lake, NJ, June 27, 2012 - Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved...
-
Jun 22, 2012
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announces the immediate appointment of Shaji Procida to the position of...
-
May 30, 2012Company Recognized for Outstanding Contributions to the Pharmaceutical Sciences
Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that The American Association of Pharmaceutical Scientists (AAPS) has awarded its 2012...
-
May 17, 2012
Eisai announced today that 15 abstracts highlighting new study results will be presented during the 48(th) Annual Meeting of the American Society...
-
May 10, 2012New Territories Include Canada, Mexico and Brazil
SAN DIEGO, CA, and WOODCLIFF LAKE, NJ, May 10, 2012 -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today the expansion of the lorcaserin marketing and supply agreement...
-
May 10, 2012
SAN DIEGO, CA, and WOODCLIFF LAKE, NJ, May 10, 2012 -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today that the US Food and Drug Administration (FDA) Endocrinologic and...
-
Apr 30, 2012
Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd., today announces the immediate appointment of Allen Waxman to the position of Senior Vice...
-
Apr 30, 2012H3 Biomedicine to employ Horizon's unique gene editing technology and isogenic cell lines to validate genetically defined drug targets for development of cancer therapeutics
Horizon Discovery Ltd (Horizon), a leading provider of research tools to support the development of personalized medicines, and
-
Apr 19, 2012
Eisai announced today that the company has amended the licensing agreement with Teikoku Pharma USA, Inc. (TPU), a subsidiary of Teikoku Seiyaku...
-
Apr 18, 2012
Eisai Inc. announced today that the results of the study, "Randomized Phase III Study 306: Adjunctive Perampanel for Refractory Partial-Onset...
-
Apr 16, 2012Clinical Study Seeks to Evaluate MORAb-004 plus best supportive care for Extending Progression-Free Survival of Patients with Chemorefractory Metastatic Colorectal Cancer
Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has commenced a multi-center, Phase II study evaluating the safety and efficacy of...
-
Mar 27, 2012Morphotek®, Inc. Announces Completion of Enrollment in the FAR-131 Trial for Relapsed Ovarian CancerClinical Study Seeks to Evaluate Farletuzumab in Combination with Standard of Care in First-Relapse Patients with Platinum-Sensitive Ovarian Cancer
Morphotek®, Inc., a subsidiary of Eisai Inc., announced today it has completed enrollment of the FAR-131 clinical trial. The study is a pivotal Phase 3...
-
Mar 7, 2012
Woodcliff Lake, NJ, March 6, 2012 - Eisai Inc. today announced that the company has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its supplemental New...
-
Mar 5, 2012
Woodcliff Lake, NJ, March 5, 2012 - Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review Eisai's resubmission of the New Drug Application (NDA)...
-
Feb 10, 2012
On February 9, 2012, the U.S. Food and Drug Administration's (FDA's) Oncologic Drugs Advisory Committee (ODAC) voted 10 to 3 with one abstention that the data in the company's...
-
Feb 1, 2012
SAN DIEGO, CA, and WOODCLIFF LAKE, NJ, February 1, 2012 - Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today that the US Food and Drug Administration (FDA) has notified...
-
Jan 30, 2012Two Innovative Programs Will Help Eliminate Lymphatic Filariasis By 2020
Tokyo, Japan, January 30, 2012 -- Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai"), as one of the thirteen major research and development-based pharmaceutical...
-
Jan 10, 2012
SAN DIEGO and WOODCLIFF LAKE, N.J., Jan. 10, 2012 -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today that the US Food and Drug Administration (FDA) has accepted for...